Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Peptide receptor radionuclide therapy (PRRT) is an effective treatment for neuroendocrine tumors (NETs) when surgery is not feasible.
• NETs often overexpress somatostatin receptors (SST), making them targets for SST analog-based imaging and therapy.
• Current PRRT achieves good results, but complete responses are infrequent, necessitating further research for improvement.

Approach:

• This review highlights emerging strategies in pilot clinical studies and preclinical development to enhance PRRT efficacy.
• Investigated approaches include using alternative radionuclides (e.g., alpha-emitters), radionuclide combinations, and modified administration routes.
• Personalized dosimetry and improved understanding of radiation doses to tumors and organs are explored for tailored treatment schedules.

Key Points:

• Novel radiolabeled SST analogs with enhanced tumor uptake and retention are under development.
• Combining PRRT with other systemic therapies like chemotherapy or radiosensitizers is being explored.
• Early studies suggest potential benefits from different radionuclides and administration strategies, though randomized trials are pending.

Conclusions:

• Promising research directions aim to significantly improve PRRT outcomes for NET patients.
• Further investigation, including randomized clinical trials, is crucial to validate these novel approaches and optimize personalized treatment strategies.